Cheryl Arrowsmith

Cheryl H. Arrowsmith is a Canadian structural biologist and is the Chief Scientist at the Toronto laboratory of the Structural Genomics Consortium. Her contributions to protein structural biology[1] includes the use of NMR and X-ray crystallography to pursue structures of proteins on a proteome wide scale.

She received her Ph.D. in chemistry at the University of Toronto in 1987 and post-doctoral training at Stanford University working with Professor Oleg Jardetzky. One of her areas of interest is the tumour suppressor p53 and related proteins.[2]

Her current research is to determine the 3-dimensional structures of human proteins of therapeutic relevance by structural proteomics.[3] She made significant contributions to epigenetic signaling with her highest cited paper is "Epigenetic protein families: a new frontier for drug discovery"[4] cited at 802 times, according to Google Scholar.[5]

Arrowsmith was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2015.[6]

References

  1. ↑ "Cheryl H. Arrowsmith". uhnresearch.ca. Retrieved December 27, 2017.
  2. ↑ "Cheryl Arrowsmith". utoronto.ca. Retrieved December 27, 2017.
  3. ↑ Chandonia JM, Brenner SE (January 2006). "The impact of structural genomics: expectations and outcomes". Science. 311 (5759): 347–51. doi:10.1126/science.1121018. PMID 16424331.
  4. ↑ Cheryl H. Arrowsmith, Chas Bountra, Paul V. Fish, Kevin Lee & Matthieu Schapira. Epigenetic protein families: a new frontier for drug discovery. Nature Reviews Drug Discovery 11, 384–400 (2012)
  5. ↑ "Cheryl Arrowsmith". scholar.google.com. Retrieved December 27, 2017.
  6. ↑ "Arrowsmith named AAAS Fellow". utoronto.ca. Retrieved December 27, 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.